{3-[(4-fluoro-benzenesulfonyl)-methyl-amino]-1,2,3,4-tetrahydro-pyrido[1,2-a]indol-10-yl}-acetic acid | 1187081-17-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: {3-[(4-fluoro-benzenesulfonyl)-methyl-amino]-1,2,3,4-tetrahydro-pyrido[1,2-a]indol-10-yl}-acetic acid
• 英文别名: 2-[3-[(4-Fluorophenyl)sulfonyl-methylamino]-1,2,3,4-tetrahydropyrido[1,2-a]indol-10-yl]acetic acid
• CAS: 1187081-17-9
• 化学式: C₂₁H₂₁FN₂O₄S
• 分子量: 416.473
• InChiKey: NYOPRXQTXYICBQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  87.5
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  {3-[(4-fluoro-benzenesulfonyl)-methyl-amino]-1,2,3,4-tetrahydro-pyrido[1,2-a]indol-10-yl}-acetic acid ethyl ester 在 甲醇 、 sodium hydroxide 作用下， 以 四氢呋喃 为溶剂， 以100%的产率得到{3-[(4-fluoro-benzenesulfonyl)-methyl-amino]-1,2,3,4-tetrahydro-pyrido[1,2-a]indol-10-yl}-acetic acid
  参考文献：
  名称：

  Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine model of allergic rhinitis

  摘要：

  The synthesis of a series of tricyclic antagonists for the prostaglandin D(2) receptor DP2 (CRTH2) is disclosed. The activities of the compounds were evaluated in a human DP2 binding assay and a human whole blood eosinophil shape change assay. Potential metabolic liabilities of the compounds were addressed through in vitro CYP studies. The lead compound was demonstrated to have efficacy in a mouse model of allergic rhinitis following oral dosing. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.06.085

文献信息

• Indole derivatives as crth2 receptor antagonists
  申请人：Wang Zhaoyin

  公开号：US20090286825A1

  公开（公告）日：2009-11-19

  Compounds according to formula (I) wherein the radicals R 1 , R 2 and R 3 are as herein defined, and wherein Ar represents an aryl group or heteroaryl group, preferably phenyl, n is 1 or 2, and the radical X represents a group selected from —C(R a )(R b )—, —C(R a )(R b )—C(R a )(R b )—, —C(R a )═C(R a )—, OC(R a )(R b )— or SC(R a )(R b )—. These compounds and their pharmaceutical acceptable salts are used in pharmaceutical compositions as prostaglandine D2 receptor antagonists useful in the treatment of CRTH2-mediated diseases such as respiratory, inflammatory or allergic conditions among others.

  化合物的公式为（I），其中基团R1、R2和R3如所定义，Ar代表芳基或杂芳基，优选苯基，n为1或2，基团X代表从—C（Ra）（Rb）—，—C（Ra）（Rb）—C（Ra）（Rb）—，—C（Ra）═C（Ra）—，OC（Ra）（Rb）—或SC（Ra）（Rb）—中选择的基团。这些化合物及其药学上可接受的盐用于制备药物组合物，作为前列腺素D2受体拮抗剂，对治疗CRTH2介导的疾病，如呼吸系统、炎症或过敏等病症有用。
• TRICYCLIC COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS
  申请人：Stearns Brian Andrew

  公开号：US20120004233A1

  公开（公告）日：2012-01-05

  Described herein are antagonists of PGD 2 receptors. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists of PGD 2 receptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD 2 -dependent or PGD 2 -mediated conditions or diseases.

  本文描述了PGD2受体拮抗剂。还描述了包括本文所述化合物的制药组合物和药物，以及使用这些PGD2受体拮抗剂的方法，单独或与其他化合物结合，用于治疗呼吸系统、心血管系统和其他PGD2依赖性或PGD2介导的疾病或病症。
• [EN] TRICYCLIC COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS<br/>[FR] COMPOSÉS TRICYCLIQUES EN TANT QU'ANTAGONISTES DES RÉCEPTEURS D2 DE LA PROSTAGLANDINE
  申请人：AMIRA PHARMACEUTICALS INC

  公开号：WO2010085820A3

  公开（公告）日：2010-11-25
• INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS
  申请人：Merck Canada Inc.

  公开号：EP1915372B1

  公开（公告）日：2013-11-20
• US7696222B2
  申请人：——

  公开号：US7696222B2

  公开（公告）日：2010-04-13